These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2525078)

  • 1. The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting.
    Green JA; Watkin SW; Hammond P; Griggs J; Challoner T
    Cancer Chemother Pharmacol; 1989; 24(2):137-9. PubMed ID: 2525078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
    Grunberg SM; Stevenson LL; Russell CA; McDermed JE
    J Clin Oncol; 1989 Aug; 7(8):1137-41. PubMed ID: 2526864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis.
    Rosso R; Campora E; Cetto G; Fosser V; Marangolo M; Oliva C
    Anticancer Res; 1991; 11(2):937-9. PubMed ID: 1829602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
    Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
    N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting.
    Marty M; Droz JP; Pouillart P; Paule B; Brion N; Bons J
    Cancer Chemother Pharmacol; 1989; 23(6):389-91. PubMed ID: 2523762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F).
    Campora E; Vidili G; Oliva C; Ardizzoni A; Rosso R
    Oncology; 1991; 48(5):403-5. PubMed ID: 1836058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.
    Viner CV; Selby PJ; Zulian GB; Gore ME; Butcher ME; Wootton CM; McElwain TJ
    Cancer Chemother Pharmacol; 1990; 25(6):449-53. PubMed ID: 2138064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
    Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
    N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
    Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
    J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.
    Pinkerton CR; Williams D; Wootton C; Meller ST; McElwain TJ
    Arch Dis Child; 1990 Aug; 65(8):822-5. PubMed ID: 2144721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.
    Cunningham D; Hawthorn J; Pople A; Gazet JC; Ford HT; Challoner T; Coombes RC
    Lancet; 1987 Jun; 1(8548):1461-3. PubMed ID: 2885454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
    Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
    Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
    Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
    J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
    Marty M
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S41-5. PubMed ID: 2533898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
    De Mulder PH; Seynaeve C; Vermorken JB; van Liessum PA; Mols-Jevdevic S; Allman EL; Beranek P; Verweij J
    Ann Intern Med; 1990 Dec; 113(11):834-40. PubMed ID: 2146911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.
    Kaasa S; Kvaløy S; Dicato MA; Ries F; Huys JV; Royer E; Carruthers L
    Eur J Cancer; 1990 Mar; 26(3):311-4. PubMed ID: 2141487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis.
    Roila F; Bracarda S; Tonato M; Marangolo M; Bella M; Donati D; Cetto G; Del Favero A
    Clin Oncol (R Coll Radiol); 1990 Sep; 2(5):268-72. PubMed ID: 2148109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.